Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             87 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp. Rhomberg, Paul R
 2001
 1-2 p. 45-49
5 p.
 artikel
2 Activity of cefepime, cefotaxime, ceftazidime, and aztreonam against extended-spectrum-producing isolates of Klebsiella pneumoniae and Escherichia coli from Chilean hospitals Zemelman, Claudia
 2001
 1-2 p. 41-43
3 p.
 artikel
3 Activity of faropenem against resistant isolates of Streptococcus pneumoniae Black, Jennifer A
 2001
 1-2 p. 89-92
4 p.
 artikel
4 AMPLICOR™ MTB polymerase chain reaction test for identification of Mycobacterium tuberculosis in positive difco ESP II broth cultures Hernandez, Antonio
 1997
 1-2 p. 17-20
4 p.
 artikel
5 Antigonococcal activity of 11 drugs used for therapy or prophylaxis of malaria Mehaffey, Phillip C.
 1995
 1-2 p. 11-13
3 p.
 artikel
6 Antimicrobial activity of cefotaxime tested against infrequently isolated pathogenic species (unusual pathogens) Cormican, Martin G.
 1995
 1-2 p. 43-48
6 p.
 artikel
7 Antimicrobial activity of RU-66647, a new ketolide Jones, Ronald N.
 1997
 1-2 p. 7-12
6 p.
 artikel
8 A retrospectiv analysis of twiec-daily cefotaxime compared to conventional therapy from the treatment of infection in a USA hospital Burk, John P.
 1995
 1-2 p. 167-169
3 p.
 artikel
9 A team approach to hospital formulary replacement Lee, Jiyeun
 1995
 1-2 p. 239-242
4 p.
 artikel
10 A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion Liebowitz, Lynne D
 2001
 1-2 p. 27-33
7 p.
 artikel
11 Bactericidal activity of cefotaxime, desacetylcefotaxime, rifampin, and various combinations tested at cerebrospinal fluid levels against penicillin-resistant Streptococcus pneumoniae Cormican, Martin G.
 1995
 1-2 p. 119-123
5 p.
 artikel
12 Can antimicrobial activity be sustained? an appraisal of orally administered drugs used for respiratory tract infections Jones, Ronald N.
 1997
 1-2 p. 21-28
8 p.
 artikel
13 Cefditoren in vitro activity and spectrum: a review of international studies using reference methods Jones, Ronald N.
 2001
 1-2 p. 1-14
14 p.
 artikel
14 Cefotaxime Wiedemann, Bernd
 1995
 1-2 p. 5-12
8 p.
 artikel
15 Cefotaxime and ceftriaxone use evaluation in pediatrics Lee, Carlton K.K.
 1995
 1-2 p. 231-233
3 p.
 artikel
16 Cefotaxime and desacetylcefotaxime antimicrobial interactions Jones, Ronald N.
 1995
 1-2 p. 19-33
15 p.
 artikel
17 Cefotaxime and metronidazole in severe intra-abdominal infection Aprahamian, Charles
 1995
 1-2 p. 183-188
6 p.
 artikel
18 Cefotaxime for the 1990s Lode, Hartmut
 1995
 1-2 p. 1-3
3 p.
 artikel
19 Cefotaxime for treatment of neonatal sepsis and meningitis Odio, Carla M.
 1995
 1-2 p. 111-117
7 p.
 artikel
20 Cefotaxime in the treatment of staphylococcal infections Aldridge, Kenneth E.
 1995
 1-2 p. 195-201
7 p.
 artikel
21 Cefotaxime twice daily versus ceftriaxone once daily Simmons, B.P.
 1995
 1-2 p. 155-157
3 p.
 artikel
22 Cefotaxime use in pediatric infections Dajani, Adnan S.
 1995
 1-2 p. 105-110
6 p.
 artikel
23 Cefotaxime versus ceftriaxone for the treatment of nosocomial pneumonia results of a multicenter study Shah, Pramod M.
 1995
 1-2 p. 171-172
2 p.
 artikel
24 Cephalosporin-metronidazole combinations in the management of intra-abdominal infection Nicolau, David P.
 1995
 1-2 p. 189-194
6 p.
 artikel
25 Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study Hoban, D.J
 2001
 1-2 p. 51-57
7 p.
 artikel
26 Comparison of SeroMP IgA with four other commercial assays for serodiagnosis of Mycoplasma pneumoniae pneumonia Watkins-Riedel, Thomas
 2001
 1-2 p. 21-25
5 p.
 artikel
27 Comparison of the Velogene Rapid MRSA Identification Assay, Denka MRSA-Screen Assay, and BBL Crystal MRSA ID System for rapid identification of methicillin-resistant Staphylococcus aureus Arbique, Judy
 2001
 1-2 p. 5-10
6 p.
 artikel
28 Development of a ceuE-based multiplex polymerase chain reaction (PCR) assay for direct detection and differentiation of Campylobacter jejuni and Campylobacter coli in Thailand Houng, Huo-Shu H.
 2001
 1-2 p. 11-19
9 p.
 artikel
29 Econotherapeutics Roark, Michael K.
 1995
 1-2 p. 209-217
9 p.
 artikel
30 Editorial Board 1995
 1-2 p. iii-
1 p.
 artikel
31 Editorial Board 1995
 1-2 p. IFC-
1 p.
 artikel
32 Editorial Board 1997
 1-2 p. iii-
1 p.
 artikel
33 Efficacy of beta-lactam antibiotics: Integration of pharmacokinetics and pharmacodynamics Cars, Otto
 1997
 1-2 p. 29-33
5 p.
 artikel
34 Emergence of methicillin-resistant Staphylococcus aureus as a community pathogen Bukharie, Huda A
 2001
 1-2 p. 1-4
4 p.
 artikel
35 Emerging Infections 4 Balows, Albert
 2001
 1-2 p. 77-78
2 p.
 artikel
36 Evaluation of Immuno-1 toxoplasma IgG assay in the prenatal screening of toxoplasmosis Rao, Lokinendi V.
 1997
 1-2 p. 13-15
3 p.
 artikel
37 Evaluation of new technology in the clinical microbiology laboratory Jenkins, Stephen G.
 1995
 1-2 p. 53-60
8 p.
 artikel
38 Evaluation of the upgraded amplified mycobacterium tuberculosis direct test (gen-probe) for direct detection of mycobacterium tuberculosis in respiratory and non-respiratory specimens Alcalá, Luis
 2001
 1-2 p. 51-56
6 p.
 artikel
39 Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis Rimola, Antoni
 1995
 1-2 p. 141-145
5 p.
 artikel
40 Four-year prospective evaluation of community-acquired bacteremia: epidemiology, microbiology, and patient outcome Lark, Rebecca L
 2001
 1-2 p. 15-22
8 p.
 artikel
41 Health care reform in the 1990s and the clinical microbiology laboratory Baron, Ellen Jo
 1995
 1-2 p. 75-76
2 p.
 artikel
42 Healthcare reform in the 1990s and the clinical microbiology laboratory Doern, Gary V.
 1995
 1-2 p. 15-16
2 p.
 artikel
43 Immunodiagnosis of fasciolosis using recombinant procathepsin L cystein proteinase Carnevale, Silvana
 2001
 1-2 p. 43-49
7 p.
 artikel
44 Impact of CLIA 88 on the Clinical microbiology laboratory Chapin, Kimberle
 1995
 1-2 p. 35-43
9 p.
 artikel
45 Impact of technological developments and organizational strategies on clinical laboratory cost reduction Staneck, Joseph L.
 1995
 1-2 p. 61-73
13 p.
 artikel
46 Influence of managed care and health maintenance organizations on the clinical microbiology laboratory Scott, David R.
 1995
 1-2 p. 17-21
5 p.
 artikel
47 Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins Craig, William A.
 1995
 1-2 p. 89-96
8 p.
 artikel
48 In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens Dubois, Jacques
 2001
 1-2 p. 35-40
6 p.
 artikel
49 In vitro killing of penicillin-suseceptible, -intermediate, and -resistant strains of streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: A comparison of bactericidal and inhibitory activity with achievable CSF levels Stratton, Charles W.
 1995
 1-2 p. 35-42
8 p.
 artikel
50 In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations Krueger, Todd S.
 2001
 1-2 p. 71-78
8 p.
 artikel
51 In vitro susceptibility study of BMS-284756 against legionella species Dubois, Jacques
 2001
 1-2 p. 79-82
4 p.
 artikel
52 Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals Forward, K.R.
 2001
 1-2 p. 57-63
7 p.
 artikel
53 Multicenter prospective surveillance of oral Candida dubliniensis among adult Brazilian human immunodeficiency virus-positive and AIDS patients Milan, Eveline Pı́polo
 2001
 1-2 p. 29-35
7 p.
 artikel
54 Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox® Antimicrobial Potency Study (ZAPS) in the United States Jones, Ronald N.
 2001
 1-2 p. 59-66
8 p.
 artikel
55 Neisseria meningitidis with decreased susceptibility to penicillin: Report from the SENTRY antimicrobial surveillance program, North America, 1998–99 Richter, S.S.
 2001
 1-2 p. 83-88
6 p.
 artikel
56 Optimizing detection of microbial sepsis Boschman, Cynthia R.
 1995
 1-2 p. 1-9
9 p.
 artikel
57 Parasitic screening of a refugee population in Illinois Peterson, Mary H
 2001
 1-2 p. 75-76
2 p.
 artikel
58 Pharmacodynamic (kinetic) considerations in the treatment of moderately sever infections with cefotaxime Turnidge, John D.
 1995
 1-2 p. 57-69
13 p.
 artikel
59 Pharmacoeconomics of appropriate antimicrobial use Davey, Peter
 1995
 1-2 p. 225-229
5 p.
 artikel
60 Pharmacokinetics of cefotaxime and desacetylcefotaxime in the young Kearns, Gregory L.
 1995
 1-2 p. 97-104
8 p.
 artikel
61 Pharmacokinetics of cefotaxime in dialysis patients Andrassy, K.
 1995
 1-2 p. 85-87
3 p.
 artikel
62 Pharmacokinetics of cefotaxime in healthy volunteers and patients Patel, Kalpana B.
 1995
 1-2 p. 49-55
7 p.
 artikel
63 Proposed quality control guidelines for National Committee for Clinical Laboratory Standards Susceptibility Tests using the veterinary antimicrobial agent tiamulin Pfaller, Michael A
 2001
 1-2 p. 67-70
4 p.
 artikel
64 Prospective evaluation of twice-daily cefotaxime in the treatment of hospitalized patients with severe infections Keller, Claus
 1995
 1-2 p. 159-161
3 p.
 artikel
65 Quality management and the clinical microbiology laboratory Baron, Ellen Jo
 1995
 1-2 p. 23-34
12 p.
 artikel
66 Rapid methods to isolate Cryptosporidium DNA from frozen feces for PCR Ward, Lucy A.
 2001
 1-2 p. 37-42
6 p.
 artikel
67 Retrospective analysis of the clinical and economic outcomes of twice-daily dosing of cefotaxime in a Canadian Tertiary Care Institution Tin, Ling Yam
 1995
 1-2 p. 135-140
6 p.
 artikel
68 Retrospective analysis of the efficacy of cefotaxime sodium dosed twice daily Bergquist, S.-O.
 1995
 1-2 p. 163-166
4 p.
 artikel
69 Review and reassessment of dosing schedules for cefotaxime in selected medical indications Young, Lowell S.
 1995
 1-2 p. 147-154
8 p.
 artikel
70 Role of oral antibiotics in treatment of community-acquired lower respiratory tract infections Legnani, Delfino
 1997
 1-2 p. 41-47
7 p.
 artikel
71 Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics Nix, David E.
 1995
 1-2 p. 71-76
6 p.
 artikel
72 Selection of cephalosporins for hospital formularies Wilson, Walter R.
 1995
 1-2 p. 129-134
6 p.
 artikel
73 Study of cefotaxime twice daily for the therapy of postoperative pneumonia Bruch, Hans-Peter
 1995
 1-2 p. 203-207
5 p.
 artikel
74 Summation Jones, Ronald N.
 1995
 1-2 p. 243-247
5 p.
 artikel
75 Switch therapy in community-acquried pneumonia Ramirez, Julio A.
 1995
 1-2 p. 219-223
5 p.
 artikel
76 The antibiotic treatment of acute otitis media and sinusitis in children Cohen, Robert
 1997
 1-2 p. 35-39
5 p.
 artikel
77 The changing role of the clinical microbiology laboratory director results of a survey Thomson Jr., Richard B.
 1995
 1-2 p. 45-51
7 p.
 artikel
78 The future—can we learn from the past? Craig, William A.
 1997
 1-2 p. 49-53
5 p.
 artikel
79 The in vitro activity of cefotaxime versus bacteria involved in selected infections of hospitalized patients outside of the intensive care unit Doern, Gary V.
 1995
 1-2 p. 13-17
5 p.
 artikel
80 Therapeutic exchange of cefotaxime for ceftriaxone: Evaluation, implementation, and subsequent cost savings at a 300-bed community hospital Rawlings, Rick D.
 1995
 1-2 p. 235-237
3 p.
 artikel
81 Therapeutic options for cefotaxime in the management of bacterial infections Raddatz, Janet K.
 1995
 1-2 p. 77-83
7 p.
 artikel
82 The role of cefotaxime in the treatment of surgical infection Wittmann, Dietmar H.
 1995
 1-2 p. 173-182
10 p.
 artikel
83 Two-year surveillance on fluconazole susceptibility of Candida spp isolates in a general and university hospital in Rome Piero Testore, Gian
 2001
 1-2 p. 23-27
5 p.
 artikel
84 Update on the use of cefotaxime for pediatric meningitis in Portugal Lecour, Henrique
 1995
 1-2 p. 125-127
3 p.
 artikel
85 Validation of cefditoren MIC quality control ranges by a multi-laboratory study (2001) Jones, Ronald N.
 2001
 1-2 p. 71-73
3 p.
 artikel
86 Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices Biedenbach, Douglas J.
 1997
 1-2 p. 1-5
5 p.
 artikel
87 Validation of the VITEK2 and the advance expert system with a collection of enterobacteriaceae harboring extended spectrum or inhibitor resistant β-lactamases Cantón, Rafael
 2001
 1-2 p. 65-70
6 p.
 artikel
                             87 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland